DYNAMICS OF PROSTATE CANCER RATE AND MORTALITY IN UKRAINE: CURRENT STATE OF AFFAIRS
Introduction. Prostate cancer (PC) accounts for about 12% of all malignancies in men. Over the last 10 years, there has been a significant increase in the incidence of this tumor, as evidenced by statistics.
Objectives. The purpose of this study was to analyze the dynamics of PC morbidity and mortality rate in Ukraine and its regions in recent years.
Materials and methods. The analysis of PC morbidity and mortality rates in Ukraine was performed in accordance with the 1999-2012 Bulletin of the National Cancer Registry of Ukraine. The following indicators were analyzed: raw (average) morbidity and mortality indicators standardized by age, world standard population that is widely used for indicator comparison across countries, Ukrainian standard population calculated based on the age structure of the Ukrainian population.
Results. The 1999-2018 analysis of the dynamics of prostate cancer incidence showed its growth both in Ukraine in general and in each region separately. In 1999, the incidence rate (world standard) for prostate cancer in Ukraine was 9.3 and in 2018 it was 22.1. The 1999-2018 analysis of the dynamics of mortality rate due to prostate cancer showed a clear trend towards its growth in Ukraine in general and in each region separately. In 1999, the mortality rate (world standard) due to prostate cancer in Ukraine was 2.7 and in 2018 it was already 4.1. Conclusions. The study showed a clear incremental tendency towards increased morbidity and mortality in patients with PC in Ukraine and its regions in the period from 1999 to 2012. Herewith, some gender differences were observed - both figures were significantly higher among male patients than female. Continuous increment growth of morbidity and mortality rate in patients with PC requires the revision of protocols for diagnostics and treatment of such patients.
Ferlay J, Shin H-R, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 2010; 127(12):2893-917.
Gloeckler Ries LA, Reichman ME, Lewis DR, Hankey BF, Edwards BK. Cancer survival and incidence from the Surveillance, Epidemiology, and End Results (SEER) program. Oncologist. 2003;8(6): 541-52.
Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61(2):69-90.
Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin. 2010;60(5):277-300.
Рак в Україні, 1999-2019. Бюл. нац. канцер-реєстру України. Київ, 2013; (8): 49-50.
Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin. 2012;62(1):10-29.
Jakub Dobruch, Andrzej Borówka , Artur A. Antoniewicz , Piotr Chłosta, Epidemiologia raka gruczołu krokowego: zmiany obserwowane w Polsce w latach 1991-2000, Urologia Polska, 2005/58/1
Post PN, Kil PJ, Crommelin MA, Schapers RF, Coebergh JW: Trends in incidence and mortality rates for prostate cancer before and after prostate-specific antigen introduction. A registry-based study in Southeastern Netherlands 1971-1995. Eur J Cancer 1998; 34; 705-709.
Bell, K.J., et al. Prevalence of incidental prostate cancer: A systematic review of autopsy studies. Int J Cancer, 2015. 137: 1749.
Abstract views: 247 PDF Downloads: 109